Cardiovascular aging is associated with decreased endothelial vasoreactivity and prolonged diastolic relaxation. As diminished NO signaling contributes to age-associated endothelial dysfunction, we tested the hypothesis that impaired NO signaling or bioactivity also contributes to slowed ventricular relaxation with age. Accordingly, we measured myocardial NO synthase (NOS) enzyme activity, protein abundance, and cGMP production in old (22 to 25 months) and young adult (4 to 7 months) male Wistar rats. Both NOS3 protein abundance and calcium-dependent NOS activity were elevated in old compared with young adult hearts (7.2Ϯ1.1 versus 4.2Ϯ0.6 pmol/mg protein, respectively, Pϭ0.03). However, NOS activity and protein abundance were similar in isolated myocytes, indicating that endothelial NOS likely explains the age difference. Cardiac effluent cGMP (enzyme immunoassay) was 4.8-fold higher (1794Ϯ373 fmol/min per mg heart tissue) in older versus younger hearts (Pϭ0.003). To assess NO pathway responsiveness, we administered the NOS substrate L-arginine (100 m) to isolated perfused rat hearts. Baseline isovolumic relaxation () was prolonged in old (42.9Ϯ2.5 ms, nϭ16) versus young hearts (36.0Ϯ1.9 ms, nϭ11, Pϭ0.03). L-Arginine decreased (PϽ0.001) and left ventricular end-diastolic pressure in both old and young hearts. Supporting an NO/cGMPmediating mechanism, the NO donor sodium nitroprusside reduced (maximal effect, Ϫ14Ϯ2%, nϭ5, PϽ0.001), and this lusitropic effect was attenuated by the soluble guanylyl cyclase inhibitor 1H- [1, 2, 4] oxadiazolo-[4,3,-a]quinoxalin-1-one (nϭ7, PϽ0.001). Thus, the NO-cGMP pathway is upregulated in the endothelial cells of aged hearts. L-Arginine, the NOS precursor, enhances ventricular relaxation in old and young hearts, indicating that the NOS pathway may be exploited to modulate diastolic function in aged myocardium. (Circ Res. 2001;88:97-102.) 
N ormal cardiovascular aging is associated with decreased endothelium-mediated vasodilation and slowed and delayed early ventricular relaxation. [1] [2] [3] [4] These changes may increase the likelihood for the development and progression of vascular disease and compromise hemodynamics during tachycardic stresses including exercise. 4 -6 The ageassociated decrease in vascular responsiveness suggests impaired vascular NO/endothelium-mediated signaling. [7] [8] [9] [10] More direct biochemical evidence indicates a significant age-associated decrease in the activity of NO synthase 3 (NOS3), the enzyme that catalyzes the production of NO, in rat aortae. 10 In addition to vascular function, NO also influences myocardial function via autocrine 11 and/or paracrine effects. 12, 13 By activating guanylyl cyclase, NO promotes myocyte relaxation via enhanced cGMP production. 14 In animal models, increasing NO by endogenous stimulation with substance P or bradykinin or by administering NO donors enhances both active and passive diastolic relaxation. [15] [16] [17] Paulus et al 12, 18 reported that intracoronary sodium nitroprusside (SNP) or substance P administration promotes left ventricular (LV) diastolic relaxation and end-diastolic distensibility in humans. Shah et al 14, 19 achieved similar lusitropic effects with cGMP analogues, further supporting an intermediary role of this nucleotide in mediating myocardial relaxation.
We hypothesized that impaired myocardial NO/NOS bioactivity or signaling contributes to the age-associated slowing of myocardial relaxation. To test this hypothesis, we measured the NOS activity, NOS3 protein abundance, and cGMP concentrations in the myocardium of Wistar rats, a wellestablished model for cardiac aging. 4, 5 Moreover, we located the source of cardiac NOS by measuring the activity and protein abundance of this enzyme in myocytes isolated from old and young rat hearts. The results demonstrate that, counter to our hypothesis, NO-cGMP signaling is substantially elevated in aged myocardium. We further tested whether the NO-cGMP pathway could be used to enhance diastolic performance by measuring the influence of L-arginine, the NOS substrate, on isovolumic relaxation in old and young adult rat myocardium.
Materials and Methods

Animal Model
Wistar male rats, a well-established model of cardiovascular aging demonstrating age-associated changes in vascular and myocardial function similar to those in humans, 4, 5 were bred at the Gerontology Research Center of the National Institute on Aging. We studied aged animals (nϭ42), defined as 22 to 25 months old, the age at which there is 50% mortality of the colony, and young adults (nϭ33) 4 to 7 months old and having reached sexual maturity. 4 Additional physiological studies were performed in adult male Wistar rats that were 10 to 11 months old (nϭ16).
Measurement of Myocardial NOS Enzyme Activity and Protein Abundance
NOS activity was measured in pulverized hearts from old (nϭ9) and young adult (nϭ7) rats by L-[ 14 C]arginine-to-L-[ 14 C]citrulline conversion assay as previously described. 20, 21 NOS3 protein abundance was measured by Western blot as described in total heart tissue from old and young (nϭ2 each) Wistar rats using monoclonal NOS3 antibody (Transduction Laboratories). 20 To further delineate the location of the cardiac NOS3 protein, NOS activity was measured by L-[ 14 C]arginine-to-L-[ 14 C]citrulline conversion assay in myocytes isolated by collagenase digestion from hearts of old and young rats (nϭ4 each). 22, 23 In addition, NOS3 protein abundance was measured by Western blotting as described above in both the cytosolic and particulate (membrane) fractions of the isolated myocytes, separated by centrifugation at 100g for 60 minutes, from old and young adult hearts (nϭ2 each).
Cardiac Effluent and Tissue cGMP Levels
Quantitative assays for cGMP from both isolated heart effluent and cardiac tissue were performed using a commercial enzyme immunoassay kit (Amersham Pharmacia Biotech, Piscataway, NJ). Effluent solution was collected from isolated retrograde-perfused rat hearts (nϭ11 old and nϭ10 young). For myocardial cGMP content, frozen heart tissue (nϭ6 old and nϭ5 young) was homogenized in 6% trichloroacetic acid (1 mL trichloroacetic acid/100 mg tissue), centrifuged, and extracted with water-saturated diethyl ether as previously described. 24 The aqueous layer was vacuum dried at Ϫ60°C and resuspended in sodium acetate buffer.
Physiological Assessment: Isovolumic Relaxation
The physiological impact of the cardiac NO/NOS signaling pathway on isovolumic relaxation, measured as , 25 was assessed in isolated retrograde perfused hearts from old (nϭ16) and young (nϭ11) rats by infusing L-arginine (100 mol/L), the NOS substrate. 26 This concentration of L-arginine is similar to that shown to improve endothelial function and symptoms of angina pectoris in humans. 27 The specificity of L-arginine was tested by infusing D-arginine (100 mol/L) in additional identically prepared hearts from adult animals (10 to 11 months old, nϭ4). Excised hearts were perfused with fixed coronary blood flow to avoid performance changes related to the Gregg effect 28 and paced at constant heart rate as previously described. 29 Care was taken to assure that each isolated heart was functioning within 90% of its peak Frank-Starling curve by titration of balloon volume. The coronary perfusion pressure and LV pressures were monitored continuously. Digitized data were analyzed to determine the rate of rise of LV pressure (peak ϩdP/dt) and the time course of isovolumic relaxation (; method of Weiss et al 25 ) . Hearts were allowed to stabilize for 15 minutes before baseline physiological parameters were recorded. Then, after a 15-minute infusion of the NOS substrate L-arginine (100 mol/L) or its inactive isomer D-arginine (100 mol/L), baseline parameters were rerecorded.
To further explore the hypothesis that observed lusitropic responses were related to NO/cGMP signaling, we infused the NO donor SNP (10 Ϫ10 to 10 Ϫ7 mol/L) to additional isolated perfused rat hearts from male animals (10 to 11 months old, nϭ5). SNP infusions (10 Ϫ8 to 10 Ϫ6 mol/L) were also performed in hearts pretreated with the guanylyl cyclase inhibitor 1H- [1, 2, 4] oxadiazolo-[4,3,a]quinoxalin-1-one (ODQ, 10 mol/L, nϭ7). The Johns Hopkins University School of Medicine Animal Care and Use Committee approved all animal protocols.
Statistical Analysis
Comparisons between old and young adult rats were made using unpaired Student t tests, whereas comparisons before and during L-arginine and D-arginine were made using paired Student t tests. Concentration-effect responses to SNP with and without ODQ were analyzed using 2-way ANOVA. Results are presented as the meanϮSEM.
Results
NOS Activity: Biochemical Assessment
Calcium-dependent NOS activity was 7.2Ϯ1.1 pmol/mg heart protein in old (nϭ9) compared with 4.2Ϯ0.6 in young (nϭ7, Pϭ0.03, Figure 1A ) adult rat hearts. The increased NOS activity with age was associated with a 40% increase in NOS3 protein abundance in heart extract from old compared with young adult rats ( Figure 1B , nϭ2 each). In contrast to whole-heart extracts, there was no difference in calciumdependent NOS activity from isolated, purified myocytes (0.52Ϯ0.23 pmol/mg protein in old versus 0.53Ϯ0.19 in young adult rats [nϭ4 each, PϭNS]). Furthermore, there were no differences in NOS3 protein abundance (detected only in the membrane fraction) in isolated myocytes from hearts of the 2 age groups ( Figure 1C ), suggesting that the age-associated increased NOS3 is of endothelial, rather than of myocyte, origin. Whereas calcium-independent NOS (NOS2) activity was not detectable in old hearts, the activity was 0.42Ϯ0.09 pmol/mg protein in young adult hearts. Consistent with the age-associated increase in NOS3 activity, the level of cGMP in cardiac effluent was 1794Ϯ373 fmol/min per mg tissue in hearts from old animals (nϭ11) and 375Ϯ58 in hearts from young animals (nϭ10, Pϭ0.003, Figure 2 ). Finally, concentrations of cGMP within heart tissue extracts were higher in the old animals (9.7Ϯ1.1 pmol/g, nϭ6) than in the young animals (6.7Ϯ0.7 pmol/g, nϭ5, Pϭ0.05).
NOS Pathway Activity: Physiological Response to L-Arginine
Despite no age differences in mean body weight (537Ϯ19 g in the older and 507Ϯ19 g in the younger rats), the mean heart weight of older rats was 2.39Ϯ0.12 g compared with a mean of 1.61Ϯ0.04 g in those from the young adults (PϽ0.0005). This increase in heart weight-to-body weight ratio with increasing age is consistent with previous reports of age-associated cardiac hypertrophy in this model. 5 Additionally, the mean ventricular balloon was 0.44Ϯ0.03 mL in hearts from aged animals compared with 0.34Ϯ0.02 mL in young adults (PϽ0.005). Table 1 depicts baseline physiological parameters of isolated hearts from old (nϭ16) and young adult (nϭ11) rats in the absence and presence of L-arginine. was 42.9Ϯ2.5 ms in old hearts and 36.0Ϯ1.9 ms in young adult hearts (Pϭ0.03, Figure 3 ) at matched LV end-diastolic pressures (LVEDPs). During the infusion of L-arginine, shortened to 33.0Ϯ2.3 ms in old (PϽ0.0001) and to 29Ϯ2.4 ms in young (Pϭ0.005) adult hearts ( Figure 3 , Table 1 ). In the presence of L-arginine, was no longer elevated in old compared with young hearts. LVEDP, which was similar at baseline in old and young adult hearts (Table 1) , was also reduced by L-arginine despite fixed LV end-diastolic balloon volume. The magnitudes of the reduction from baseline, 7.9Ϯ1.9 mm Hg in old (PϽ0.01) and 6.6Ϯ2.1 in young adult (PϽ0.01) hearts, were similar in the 2 age groups ( Table 1) . Peak ϩdP/dt was lower in older than in younger adult hearts and was not altered by L-arginine in either age group (Table 1) . In contrast to L-arginine, infusion of D-arginine did not change (39.5Ϯ0.5 and 39.2Ϯ0.4 ms, before and after D-arginine, respectively, PϭNS) or LVEDP (24.7Ϯ0.3 and 25.0Ϯ0.7 mm Hg before and after D-arginine, respectively, PϭNS) when infused into hearts isolated from adult rats (10 to 11 months old, nϭ4).
Similar to the response to L-arginine, the NO donor SNP (10 Ϫ10 to 10 Ϫ7 mol/L) shortened and reduced LVEDP ( Table  2 and Figure 4 ). In contrast, after pretreatment with the guanylyl cyclase inhibitor ODQ, the lusitropic effect of SNP, reflected by the change in both and LVEDP, was attenuated ( Figure 3 ). These data provide additional evidence that the lusitropic response to L-arginine is likely due to activation of the NO and/or cGMP pathways. 
TABLE 1. Baseline Physiological Parameters From Isolated Retrograde Perfused Hearts From Old (22 to 24 Months) and Young Adult (4 to 6 Months) Rats in the Absence and Presence of L-Arginine
Discussion
In this study, we sought to extend observations regarding aging vasculature to ventricular myocardial function. In the vasculature, reduced NOS activity likely contributes to decreased endothelium-dependent vasoreactivity with increasing age. 7-10 Accordingly, we tested the hypothesis that diminished NO contributes to prolonged diastolic relaxation in aged myocardium. Our results demonstrate that rat myocardial NOS activity is not only intact, but upregulated with age. Specifically, calcium-dependent NOS activity and protein abundance were elevated in hearts from older animals, and these increases were of endovascular, rather than of myocyte, origin. Furthermore, cGMP concentrations in both myocardial tissue and cardiac effluent were increased with age. The NOS precursor L-arginine induced a potent lusitropic effect in both old and young adult rat hearts, eliminating the baseline age-related prolongation in isovolumic relaxation. Thus, cardiac NOS activity is elevated with increasing age and provides a potential target for modulating ventricular relaxation.
Cardiac NOS Abundance and Activity
Our biochemical findings of elevated cardiac NOS are consistent with those of Cernadas et al, 10 who reported an age-associated increase in the expression of NOS2 and NOS3 and cGMP levels in the aortae of Wistar rats. Yet, despite this increased NOS expression, both NOS3 activity and the vasodilator response to NO-dependent agonists were diminished in their study, possibly explaining the age-associated decrease in endothelial function. In our study, NOS3 protein abundance and enzyme activity were upregulated in aging hearts. Other settings in which increased myocardial NOS expression and activity are reported are heart failure and sepsis. 30 -32 However, an important difference relates to the upregulated NOS isoform; NOS2 activity 33 and expression 32 are increased in heart failure and sepsis.
The mechanism for increased cardiac NOS3 in aging is unknown. Unlike NOS2, which is activated by cytokines and other inflammatory factors, NOS3 expression can be enhanced by vascular shear stress, 34, 35 which could be elevated in aging as a result of increased vascular stiffening and/or raised pulse-pressure. 6 In aging, increased NOS3 expression may also reflect the known age-associated decrease in cAMP, a nucleotide that can suppress NOS3 gene expression. 36 In terms of the elevated concentrations of cGMP measured in both effluent and myocardial tissue, this likely reflects the observed increase in NOS activity. There are, however, other possible contributory factors, including the previously described increased levels of atrial natriuretic peptide, an agonist of receptor guanylyl cyclase. 37 Our finding that elevated NOS resides primarily in the endothelium of aged hearts is consistent with paracrine NO signaling in the heart. 12 Similarly, Gyurko et al 38 have reported that the majority of cardiac NO signaling originates from endothelial cells. However, the upregulation of endothelial cell NO-cGMP may serve roles in addition to cardiac paracrine signaling. For example, NO has been shown to inhibit endothelial cell apoptosis by activating telomerase. 39
NO and Diastolic Performance
As L-arginine has been shown to improve endothelial reactivity in aged vasculature, 8 we sought to determine whether this NOS precursor could promote cardiac lusitropy. L-Arginine enhanced early ventricular relaxation in both old and young hearts, as demonstrated by a reduction in , and increased chamber compliance as indicated by reduced LVEDP at constant LV end-diastolic volume. In contrast, no change in or LVEDP was present after infusion of the inactive isomer D-arginine. The mechanism by which L-arginine enhances NO signaling despite adequate intracellular levels of this substrate remains controversial 40 but has been widely documented in the setting of endothelial reactivity (see Reference 27 for example). The specific contribution of the NO-cGMP signaling pathway to enhanced lusitropy is further supported by our findings that the NO donor SNP, like L-arginine, accelerates isovolumic relaxation and enhances LV diastolic compliance and that these responses are blunted by the soluble guanylyl cyclase inhibitor ODQ.
In the current study, we did not investigate potential alterations in L-arginine availability that could lead to decreased NO production. Among the possibilities are changes in L-arginine transport 41 and/or an increase in levels of endogenous NOS inhibitors with aging, which can be overcome with increased L-arginine. 26 Consistent with the latter theory, Miyazaki et al 42 reported an age-associated increase in plasma levels of one such inhibitor, asymmetrical dimethylarginine, in humans. Another important consideration is that certain NO actions may be inhibited by oxidative inactivation, as reported in cholesterol-exposed vessels. 43 Yet, regardless of any age-associated alterations in precursor availability/metabolism or downstream NO inactivation, L-arginine administration appears to overcome them. Thus, the response to L-arginine may have important therapeutic implications, as enhanced early diastolic relaxation may increase older indi- viduals' ability to exercise and may lessen the hemodynamic consequences of tachycardic and hypertensive stresses. 6 Initially, we considered the possibility that alterations in NO-cGMP signaling contribute to age-associated changes in early diastolic relaxation, as NO has positive lusitropic properties. 12, [15] [16] [17] [18] 44 However, the fact that aged myocardium has delayed diastolic relaxation in the presence of upregulation of the NOS-cGMP pathway suggests that other factors are responsible for the prolongation of isovolumic relaxation, measured as . In this regard, prolonged intracellular calcium currents, due in part to downregulation of the sarcoplasmic reticulum Ca 2ϩ -ATPase, 45 likely contribute. 4, 5 Increased cGMP may decrease the functional consequences of this age effect by reducing myofilament sensitivity to calcium and/or by antagonizing the stimulatory effects of cAMP on L-type calcium channels. 13,14,46 -48 It is attractive to speculate that early diastolic relaxation in aged myocardium would be even slower in the absence of elevated NOS activity and that increased NOS activity in aged myocardium serves an adaptive function.
NO in the Aging Cardiovascular System
NO may have other adaptive roles in the aging cardiovascular system. Cardiac output in older individuals during exercise stress is more dependent on increased stroke volume mediated by increased LV end-diastolic volume than in younger subjects, 49 -51 and NO is known to enhance the Frank-Starling response. 52 The findings of Pinsky et al 53 that cardiac NO levels rise in response to increases in ventricular preload further supports a physiological link between NO and the Frank-Starling mechanism.
There are some limitations of our study that warrant mention. First, as our studies were performed in male animals, important gender-related alterations could not be assessed. Future studies will address the potential effects of estrogen (or lack thereof) on NOS signaling with age. 54 Second, our experiments were performed in a crystalloid perfused preparation that has the potential to either enhance or diminish NO-related signaling 55 ; further studies will be required to confirm the response to L-arginine in bloodperfused models. Additionally, future investigations will focus on the histopathological assessment of vasculature and perivascular and interstitial regions, which are likely to be altered in older humans and/or disease states and thus may limit the potential benefit of L-arginine. 56 In conclusion, we demonstrate that adult rats of advanced age exhibit increased myocardial NOS-cGMP signaling associated with increased NOS3 protein abundance. This upregulation, primarily present in cardiac endothelial cells, may be physiologically modulated to enhance ventricular relaxation by the administration of L-arginine. This response may have both physiological and therapeutic implications in the management of older individuals with disease processes associated with increased ventricular stiffness.
